Search

Displaying results 951 - 960 of 3917 in total
  1. Drug

    Valdecoxib

    go.drugbank.com/drugs/DB00580
    ApprovedWithdrawn

    Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.

    Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal
  2. Drug

    Nogapendekin alfa

    go.drugbank.com/drugs/DB18740
    ApprovedInvestigational

    [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without … [L50627] Non-muscle invasive bladder cancer (NMIBC), which accounts for 75% of all bladder tumours, is commonly treated with transurethral resection of the bladder tumour and Bacillus Calmette-Guérin (

  3. Drug

    Romiplostim

    go.drugbank.com/drugs/DB05332
    ApprovedInvestigational

    FDA approved on August 22, 2008.

  4. Drug

    Disopyramide

    go.drugbank.com/drugs/DB00280
    ApprovedInvestigational

    A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar

  5. Drug

    Dornase alfa

    go.drugbank.com/drugs/DB00003
    ApprovedInvestigational

    Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is ...

  6. Drug

    Indapamide

    go.drugbank.com/drugs/DB00808
    ApprovedInvestigational

    The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts...

    Mixtures: COVERATRIX 5 MG/1.25 MG/10 MG COMPRIMIDOS RECUBIERTOS CON PELÍCULA, COVERATRIX 10 MG / 2.5 MG / 5 MG COMPRIMIDOS RECUBIERTOS CON PELÍCULACategories: Non Potassium Sparing Diuretics
  7. Drug

    Tirzepatide

    go.drugbank.com/drugs/DB15171
    ApprovedInvestigational

    [L48766] On September 15, 2022, tirzepatide was also approved by the European Commission.[L44386]. On November 02, 2023, tirzepatide was also approved by the Health Canada [L52800] … [A246260] Its protein sequence was based on the sequence of endogenous GIP, and its pharmacological action on GLP-1 receptors is comparable to endogenous GIP; however, the long half-life of tirzepatide

  8. Drug

    Hyaluronidase

    go.drugbank.com/drugs/DB14740
    ApprovedInvestigational

    [A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338]

  9. Drug

    Eteplirsen

    go.drugbank.com/drugs/DB06014
    ApprovedInvestigational

    Eteplirsen directly works on the DMD gene to promote dystrophin production. Eteplirsen was the first treatment for DMD approved by the FDA.[A244925]

  10. Drug

    Histrelin

    go.drugbank.com/drugs/DB06788
    ApprovedInvestigationalWithdrawn

    [L41715] Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. … Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that need to be replaced every 52 weeks.